## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.3% below STRENGTH zone (4.0-10.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($130.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: 富途牛牛 | 20260101T040849 | Neutral | Relevance: 100%
- ICU Medical, Inc. (NASDAQ: ICUI) announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference. Vivek Jain, chairman and chief executive officer, is scheduled to present on Monday, January 8, 2024, at 11:15 a.m. PST. A live audio webcast of the presentation will be available for investors and interested parties.

**2. ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: GlobeNewswire | 20251231T083000 | Somewhat-Bullish | Relevance: 100%
- ICU Medical, Inc. (Nasdaq: ICUI) announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 12-15, 2026. The presentation is scheduled for January 14, 2026, at 1:30 p.m. PT (4:30 p.m. ET), with a live webcast available on the Company’s website. Company management will also participate in one-on-one meetings on the same day.

**3. ICU Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026**
- Source: Quiver Quantitative | 20251231T140927 | Somewhat-Bullish | Relevance: 100%
- ICU Medical, Inc. (Nasdaq: ICUI) announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 1:30 p.m. PT. The presentation will be available via live webcast on the company's website, with a replay option to follow. The company, a leader in infusion systems and critical care products, will also engage in one-on-one meetings during the San Francisco conference.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 17.3x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.4B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 17.3 |
| Current P/E | 18.3 |
| YoY Growth | 6.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 0.2% to -4.3% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.3pp (needs >4.0% for momentum thesis). AM_20 at -4.8% indicates price below own 20MA trend. Underperforming sector by 5.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). MACD histogram bearish (-1.33), momentum weakening. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.28% (CS: 10) | Weak |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -1.33 | Bearish |
| vs SMA20 | 0.952x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.044x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $138.53
- **Stop Loss:** $130.37 (5.9% risk)
- **Target:** $146.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 176
- **Position Value:** $24,381.28
- **Portfolio %:** 24.38%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*